Traditional Chinese medicine composition for inducing resuscitation and promoting intelligence and application thereof
By developing an oracle-enhancing and educational composition containing Chinese medicine ingredients such as aconite and ginseng, the problems of limited drug intervention effects and obvious side effects in autism treatment have been solved, and the effect of improving social and cognitive abilities has been achieved, and it has been used in clinical practice. It shows safe and effective efficacy.
Patent Information
- Application Number
- CN202411182738.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-27
AI Technical Summary
The prior art has limited drug intervention effects and obvious side effects in the treatment of autism. Especially for patients with unclear diagnosis, there is a lack of safe and effective treatment methods, and traditional Chinese medicine lacks research and application of autism.
A Chinese medicine composition that opens orals and promotes intelligence has been developed, including aconite, ginseng, dried ginger, Everrucidae, Poria cocos, Nascenti, Atractylodes, Gastrodia elata, Acorus granulum, Chuanxiong, Angelica dahurica and licorice. Through the principle of assisting the monarch and ministers, both symptoms and root causes are treated and dopamine is regulated. It can synapse, mTOR signaling pathway and circadian rhythm to promote mental recovery and qi and blood circulation.
In the experiment, the composition significantly improved the social disorder and cognitive ability of autism model mice, reversed the lack of social interest and social memory defects, and did not see any obvious side effects in clinical applications, improving the communication of children, Social and behavioral abilities.
Smart Images

Figure CN118924871A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicines and discloses a traditional Chinese medicine composition, and more specifically, relates to a traditional Chinese medicine composition for invigorating the mind and improving intelligence and an application thereof. Background Art
[0002] Autism spectrum disorders (ASD), also known as autistic disorder, are a group of heterogeneous neurodevelopmental disorders. [1] , characterized by deficits in social interaction and communication, along with restricted and stereotyped behaviors, interests, and activities [2] The prevalence of ASD is increasing worldwide [3] ASD is a lifelong disease that places a heavy burden on patients, their families, and society. Currently, the etiology and pathogenesis of ASD are not fully understood, and specific treatments are often lacking in clinical practice.
[0003] With the improvement of medical standards, the diagnosis rate of ASD children after the age of 4 continues to rise, but the clinical symptoms are not obvious (especially at the age of 2-3 years old), and there are mixed symptoms with other mental development disorders such as ADHD and mental retardation. Therefore, the diagnosis of ASD still faces huge challenges. The current drug intervention for ASD has limited effects and side effects. For example, transcranial direct current stimulation often causes adverse reactions such as skin tingling. [4] Risperidone can cause side effects such as increased appetite, fatigue, dizziness, and drowsiness [5] This has greatly limited the implementation of clinical intervention for ASD, especially for patients with unclear diagnosis.
[0004] However, research shows that intervention is critical for ASD prognosis. Detection and intervention in the first two years of life can take advantage of neural plasticity to promote the best prognosis. [6] , and can significantly improve social interaction and communication skills [7] Most importantly, the intervention encouraged the neural networks to build complex connections. [8] and improve brain development by promoting synaptic growth [9] Therefore, early use of safe and effective broad-spectrum preventive and therapeutic drugs that are beneficial or harmless to a variety of mental retardation during the most active period of neural plasticity is of great significance for improving the prognosis of ASD.
[0005] There is no clear record of autism in ancient Chinese classics and modern Chinese medicine. From the descriptions of doctors of various dynasties, we can find that in ancient Chinese medical books, developmental delay and children's mental illness are classified as "five delays and five weaknesses". Ancient Chinese medical books point out that children with "five delays and five weaknesses" often have typical symptoms such as insomnia, irritability, suspicion, loneliness, strange temper, unsociability, indifference, silence, talking to oneself, dull eyes, timidity, crying and laughing at random, strange behavior, delusions, hallucinations, memory loss, depression, emotional disorders, manic episodes, developmental delay, drowsiness, etc.
[10] This is consistent with the phenotype of many childhood psychiatric disorders, including autism, ADHD, and cerebral palsy
[11] . The etiology and pathogenesis are congenital deficiency, kidney essence deficiency; liver dysfunction, poor ascending function; spirit loss, blocked mind. Chinese medicine believes that the brain is the sea of marrow and the organ of the primordial spirit. Due to congenital deficiency, the liver and kidney are deficient, the heart and spleen are deficient, resulting in the baby's essence and qi being unable to nourish the marrow and brain, causing abnormal consciousness. This is a common dialectical thinking in Chinese medicine, so the treatment method of nourishing the liver and kidney, strengthening the spleen and nourishing the heart is often used. Chinese medicine treatment generally adopts the Yikang method
[12] , Yin-nourishing and kidney-tonifying method
[13] And through syndrome differentiation and treatment, overall consideration
[14] , give Zuoguiyin, Erchen Decoction and other compound prescriptions or their modified prescriptions
[15] , and achieved good therapeutic effects. The clinical application not only had no obvious side effects, but also had a significant improvement on the patient's physical condition, indicating that traditional Chinese medicine has better advantages in treating autism.
[0006] However, in addition to the above reasons, due to some abnormal factors during pregnancy, as well as factors such as dystocia and improper postpartum care of newborns, phlegm, blood stasis and toxins are blocked in the baby's body, so that qi and blood cannot nourish the brain, which will also lead to emptiness of the marrow sea. Therefore, the treatment of autism should take into account the congenital and acquired causes of the disease, and treat both the symptoms and the root causes. Based on this, the inventor team has formulated a Chinese medicine composition for opening up the mind and improving intelligence, which can treat congenital and acquired diseases at the same time to comprehensively improve autism. After searching, the prior art does not disclose the prescription for opening up the mind and improving intelligence in the present invention, nor does it disclose the research and application of the Chinese medicine composition for autism.
[0007] 1.Garrido, D., et al., Shank2 / 3double knockout-based screening of cortical subregions links the retrosplenial area to the loss of social memory in autism spectrum disorders. Mol Psychiatry, 2022.27(12):p.4994-5006.
[0008] 2.Zhang,J.,et al.,CNTNAP2 intracellular domain(CICD)generated bygamma-secretase cleavage improves autism-related behaviors.Signal TransductTarget Ther,2023.8(1):p.219.
[0009] 3.Arvidsson,O.,et al.,Secular changes in the symptom levelofclinically diagnosed autism.J Child Psychol Psychiatry,2018.59(7):p.744-751.
[0010] 4.Garcia-Gonzalez,S.,et al.,Transcranial direct current stimulationin Autism Spectrum Disorder:A systematic review and meta-analysis.EurNeuropsychopharmacol,2021.48:p.89-109.
[0011] 5.Al-Huseini,S.,et al.,Effectiveness andAdverse Effects ofRisperidonein Children with Autism Spectrum Disorder in aNaturalistic Clinical Settingat a University Hospital in Oman.Autism Res Treat,2022.2022:p.2313851.
[0012] 6.Bora,E.,A neurodevelopment and neuroplasticity-based framework forearly intervention in psychotic disorders.Psychol Med,2018.48(3):p.353-361.
[0013] 7.Zwaigenbaum,L.,et al.,Early Intervention for Children With AutismSpectrum Disorder Under 3Years of Age:Recommendations for Practice andResearch.Pediatrics,2015.136Suppl 1(Suppl 1):p.S60-81.
[0014] 8.Sullivan, K., WLStone, and G.Dawson, Potential neural mechanisms underlying the effectiveness of early intervention for children with autismspectrum disorder. Res Dev Disabil, 2014.35(11):p.2921-32.
[0015] 9.Petinou,K.and D.Minaidou,Neurobiological Bases of Autism SpectrumDisorders and Implications for Early Intervention:A BriefOverview.FoliaPhoniatr Logop,2017.69(1-2):p.38-42.
[0016] 10. Wei Zitai, Clinical Summary of Five Delays and Five Weaknesses. Zhejiang Journal of Traditional Chinese Medicine, 2012.47(06):p.402-403.
[0017] 11. Li Taoli and Wang Yi, Research progress on neuropsychiatric comorbidity in children with epilepsy. Journal of Fudan University (Medical Edition), 2018.45(04):p.578-584+597.
[0018] 12. Pan Rui and Huang Mao, Chief Physician Huang Mao's experience in treating cerebral palsy with the Yikang method. Journal of Hebei Traditional Chinese Medicine, 2019.34(06):p.48-51.
[0019] 13. Lu Xiaobo, et al., Clinical application of Liuwei Dihuang Wan (modified) in treating motor development retardation in children from the perspective of the theory of essence and qi. Chinese Journal of Ethnomedicine, 2019.28(14):p.87-89.
[0020] 14. Li Tuanjie and Han Xue. Exploring autism spectrum disorders in children from the perspective of Xuanfu theory. Journal of Clinical Research in Traditional Chinese Medicine, 2023.15(07):p.29-32.
[0021] 15. Tan Hongwan, et al., Research progress on TCM treatment of autism. Journal of Guangzhou University of Chinese Medicine, 2021.38(03): p.647-650.
[0022] 16.Saha, S., et al., Analysis of neurotransmitters validates theimportance of thedopaminergic system in autism spectrum disorder. World JPediatr, 2023.19(8):p.770-781.
[0023] 17. Terauchi, A., et al., The projection-specific signals that establishfunctionallysegregated dopaminergic synapses. Cell, 2023.186(18):p.3845-3861e24.
[0024] 18.Lipton, JOand M.Sahin, The neurology of mTOR. Neuron, 2014.84(2):p.275-91.
[0025] 19.Pagani, M., et al., mTOR-related synaptic pathology causes autismspectrumdisorder-associated functional hyperconnectivity. Nat Commun, 2021.12(1):p.6084.
[0026] 20.Glickman,G.,Circadian rhythms and sleep in children with autism.NeurosciBiobehav Rev, 2010.34(5):p.755-68.
[0027] 21.Nicholas,B.,et al.,Association of Per1 and Npas2 with autisticdisorder:supportfor the clock genes / social timing hypothesis.Mol Psychiatry,2007.12(6):p.581-92.
[0028] 22.Hoenicka,J.,et al.,From dopaminergic genes to psychiatricdisorders.NeurotoxRes,2007.11(1):p.61-72.
[0029] 23.Jabarin,R.,S.Netser,and S.Wagner,Beyond the three-chamber test:toward amultimodal and objective assessment of social behavior in rodents.MolAutism,2022.13(1):p.41.
[0030] 24.Kang,R.,et al.,Loss of Katnal2 leads to ependymal ciliaryhyperfunction andautism-relatedphenotypes in mice.PLoS Biol,2024.22(5):p.e3002596.
[0031] 25.Li,H.,et al.,Identification of Dopamine D1-Alpha Receptor WithinRodentNucleus Accumbens by an Innovative RNA In Situ Detection Technology.JVis Exp,2018(133).
[0032] 26. Lee, SA, et al., Functional expression of dopamine D2 receptor isregulated bytetraspanin 7-mediated postendocytic trafficking. FASEB J, 2017.31(6):p.2301-2313.
[0033] 27. Reith, MEA, et al., The dopamine transporter gene SLC6A3: multidisease risks. Mol Psychiatry, 2022.27(2):p.1031-1046.
[0034] 28.Calamito,M.,et al.,Akt1 and Akt2 promote peripheral B-cellmaturation and survival.Blood,2010.115(20):p.4043-50. Summary of the invention
[0035] In view of the deficiencies in the prior art, the present invention aims to provide a Chinese medicine composition for invigorating the mind and improving intelligence, which is used to treat autism or mental illness in children.
[0036] A Chinese medicine composition for invigorating the mind and improving intelligence is prepared from the following medicines in parts by weight: 6-60g of aconite root, 6-30g of ginseng, 6-30g of dried ginger, 3-15g of evodia rutaecarpa, 10-30g of tuckahoe, 6-30g of arisaema cinerea, 3-30g of atractylodes macrocephala, and 6-30g of gastrodia elata.
[0037] Furthermore, the Chinese medicine composition also includes 3-30g of Acorus calamus, 3-20g of Ligusticum chuanxiong, 3-30g of Angelica dahurica, and 3-10g of Licorice.
[0038] Preferably, the Chinese medicine composition is 10g of aconite, 12.5g of ginseng, 10g of dried ginger, 5g of Evodia rutaecarpa, 10g of Poria, 10g of Arisaema cinerea, 5g of Atractylodes macrocephala, 10g of Gastrodia elata, 7.5g of Acorus calamus, 5g of Ligusticum chuanxiong, 5g of Angelica dahurica, and 5g of Licorice.
[0039] The main drugs in this group are aconite and ginseng. Aconite is the most important drug for supporting yang. It has the effects of restoring yang and rescuing adverse conditions, replenishing fire and supporting yang. It is the main drug for replenishing the human body's innate heart and kidneys; ginseng is a product that greatly replenishes vital energy, and also has the effects of replenishing the spleen and lungs, promoting fluid and calming the mind. The combination of ginseng and aconite replenishes the life gate fire and fills the body's vital energy, warms yang and promotes fluid, and neither warms nor dries up, which together play a role in consolidating the human body's innate foundation and stimulating life potential.
[0040] Minister medicine: dried ginger warms the middle and dispels cold, restores yang and dredges the meridians, dries dampness and eliminates phlegm, and assists the monarch medicine aconite to warm the life gate fire of the innate kidney to generate the acquired spleen earth, so that the acquired spleen can be healthy and the spleen can disperse essence to feed the innate kidney essence, which complements each other; the classic prescription Sini Tang composed of aconite, dried ginger and licorice is the best combination to nourish the innate heart and kidney and the acquired spleen and stomach; Evodia rutaecarpa mainly enters the liver meridian, which is a product that warms the liver and reduces adverse effects. The liver is responsible for dredging, regulating emotions and cheering up the mood. It can target negative symptoms such as "autism" and "withdrawal", promote the circulation of qi and blood in the body, and assist the monarch medicine to better treat and play a role. Poria, Arisaema, Atractylodes macrocephala, and Gastrodia elata strengthen the spleen, resolve phlegm and dredge the meridians. On the basis of the monarch medicine strengthening the body, they expel phlegm evil, eliminate "phlegm confusing the brain" and promote mental recovery. Chuanxiong can promote blood circulation, remove blood stasis and promote qi circulation. It has the effect of removing blood stasis and stagnation for the blood stasis and poison that may be produced during dystocia, and better promote the circulation of qi and blood.
[0041] Auxiliary drugs: Acorus calamus opens the orifices and dispels phlegm, wakes up the mind and improves intelligence; Angelica dahurica dispels wind and dampness, and opens the orifices. The combination of the two drugs can clear away phlegm, blood stasis, and toxins that are blocked in the body, and enhance the effects of the main drugs aconite and ginseng in stimulating the circulation of qi and blood. Licorice harmonizes and adjusts the drugs, and is also a component of Sini Decoction (aconite, ginger, grass) and Lizhong Decoction (ginseng, ginger, tangerine peel, grass) included in this prescription.
[0042] Dopamine is a key neurotransmitter involved in regulating movement, emotion, reward, and social behavior. Studies have shown that dysfunction of the dopaminergic system is associated with a variety of behavioral characteristics in people with autism. [16,17] In addition, the mTOR signaling pathway plays a key role in cell growth, protein synthesis, and synaptic plasticity. Its overactivation may lead to excessive neuronal growth and synaptic overconnectivity, which is related to brain abnormalities in patients with autism. [18,19] ; At the same time, circadian rhythms regulate many physiological and behavioral processes, including the sleep-wake cycle. People with autism often report sleep problems, which may be related to mutations or abnormal expression of circadian rhythm genes [20,21] . The present invention verifies the interaction between the key genes of ASD and the drug target genes through network pharmacology to evaluate the possible pharmacodynamic pathways and potential therapeutic effects of the Kaiqiao Yizhi prescription. As shown in Example 1 of the present invention, the drugs in the Kaiqiao Yizhi prescription play a regulatory role on seven key regulatory pathways of ASD, such as dopaminergic synapses, mTOR signaling pathways, and circadian rhythm entrainment ( Figure 1-3 ). In summary, these pathways are closely related to autism, and the drugs in the Kaiqiao Yizhi prescription have a regulatory effect on these autism-related pathways, suggesting that this prescription has the potential to treat autism. Taking the dopaminergic synaptic pathway as an example, the drug target genes in the pathway can not only regulate the growth and development, movement, reward, memory and learning of neurons, but also affect important life activities such as cell proliferation and differentiation.
[22] , and can also regulate downstream autism-related genes ( Figure 4), further suggesting that the prescription for improving resuscitation and improving intelligence in the present invention may have potential value as a drug for the prevention and treatment of ASD.
[0043] The embodiment of the present invention shows a human hippocampal neuron cell (HPPNCs) culture experiment. During the experiment, the inventor set a series of concentration gradients from 0.01mg / mL to 20mg / mL according to the commonly used drug concentration intervals in conventional pharmacology research to carry out drug treatment experiments to comprehensively evaluate the effects of drugs on cell activity. According to the observation of cell activity and toxicity in preliminary experiments, the inventor selected 0.03125mg / mL, 0.0625mg / mL, 0.125mg / mL, 0.25mg / mL and 0.5mg / mL for subsequent experiments. These concentrations can effectively capture the changing trend of cell activity at different doses, ensure that the effect of the drug is evaluated within a safe range, thereby helping to determine the optimal effective concentration and avoid potential cytotoxicity. Cell activity changes were detected after 24 hours and 48 hours by the MTT method, and the results were as follows: at 24 hours, compared with the normal group, the cell activity of the 0.0625mg / mL concentration group showed an increasing trend, and other concentrations did not show this trend. At 48 hours, the 0.0625 mg / mL concentration group showed a more stable trend than other concentration groups ( Figure 5 In addition, the inventors analyzed the apoptosis of cells within 24 hours and found that compared with the normal group, the concentration of 0.0625 mg / mL did not accelerate the apoptosis of HPPNCs; compared with the positive group, this concentration could reverse the apoptosis rate and improve the activity of HPPNCs to a certain extent (see Figure 6 ). All the above results suggest that Kaiqiao Yizhi prescription has the potential to be used as a drug for the prevention and antagonism of ASD.
[0044] The embodiments of the present invention prove that the method of improving intelligence and improving the social ability of autism model mice can be used. Male wild-type C57BL / 6 (C57 / WT) mice and male BTBR T+Itpr3tf / J (BTBR / C) autism model mice were selected as experimental subjects, and the male BTBR mice were randomly divided into four groups: C group (BTBR-0.9% NaCl group), BTBR-0.5xFF group (0.32 mg / g), BTBR-1xFF group (0.64 mg / g) and BTBR-2xFF group (1.28 mg / g). Each group of mice was continuously gavaged with 10% ethyl acetate or saline for 2 weeks, and animal behavior experiments were performed before and 2 weeks after administration.
[0045] First, the open field test was used to measure the mice's residence time, movement speed, and movement distance in different areas to evaluate the mice's anxiety state. The results showed that before administration, BTBR mice had no significant differences from WT mice in total movement distance, average speed, and center distance, but the center activity time was significantly reduced, indicating that BTBR mice showed more anxiety ( Figure 7 A). After 2 weeks of administration, the total moving distance, average speed and center distance of BTBR mice increased significantly, while the center activity time recovered ( Figure 7 B). The heat map and trajectory map results also show similar trends ( Figure 8 ), indicating that this prescription can improve the anxiety behavior of BTBR mice.
[0046] Secondly, the number and time of mice exploring each object were measured by the novel object test to evaluate the mice's exploratory behavior and memory ability. The results showed that before drug administration, WT mice were more inclined to explore new objects, but BTBR mice had no difference in exploring new and old objects ( Fig. 9 A); After 2 weeks of administration, the exploration time of BTBR mice in the 0.5x and 2x administration groups increased significantly, and the exploration time of BTBR mice in the 1x administration group tended to increase, showing a similar preference for exploring new objects as WT mice ( Fig. 9 B). The heat map and trajectory map results also support this finding ( Fig.10 ), indicating that this prescription can enhance the cognitive ability of BTBR mice.
[0047] Finally, the effect of drugs on the social behavior of mice was examined through a three-box social experiment. The experiment recorded: ① The number of times and activity time of mice entering the strange mouse S1 and the empty cage E1 in the first stage; ② The number of times and activity time of mice entering the old mouse S1 and the strange mouse S2 in the second stage. In this experiment, normal mice should spend more time and more times communicating with S1 in the first stage of the experiment; in the second stage, normal mice should prefer to communicate with S2, showing good social memory and interaction ability.
[23] Abnormal mice (such as autism model mice) usually show similar interests in the room with unfamiliar mouse S1 and the room with empty cage E1, or prefer the empty cage E1, and have no significant preference between the new mouse S2 and the old mouse S1, indicating that they have a lack of social interest and social memory defects
[24] The results showed that the data from the two-stage test before the experiment could completely distinguish WT mice from BTBR mice ( Fig.11). After 2 weeks of administration, the behavioral results of the two phases of mice were classified and statistically analyzed. The results showed that the behavioral performance of BTBR mice was significantly improved. The mice in the BTBR-1xFF group tended to spend more time in contact with the unfamiliar mouse S1 in the first phase, and the social preference index (SPI) of the BTBR-1xFF group was significantly increased compared with the BTBR group fed with normal saline ( Fig.12 A). In the second stage, BTBR mice in each dosing concentration group showed stronger preference for the new mouse S2, which was closer to the performance of the WT group mice ( Fig.12 ). The heat map and trajectory map also show similar results ( Fig.13 ). This indicates that the prescription reversed the lack of social interest and social memory deficits in BTBR mice.
[0048] The prescription for improving resuscitation and improving intelligence provided by the present invention can not only significantly improve the neuronal activity of HPPNCs cells, but also improve the social level of animal models, and can be used for the treatment of autism.
[0049] Compared with the prior art, the present invention has the following beneficial effects:
[0050] 1) The present invention follows the principle of monarch, minister, assistant and envoy, with ginseng and aconite as monarch drugs, and dried ginger, evodia rutaecarpa, tuckahoe, arisaema, and gastrodia as minister drugs. Through drug compatibility and the synergistic effect of each drug, the drug composition treats both the symptoms and the root causes. Experiments show that the drug composition plays an important role in the key pathways of synaptic plasticity of brain neurons, and shows safety and effectiveness in clinical treatment. Animal experiments show that the formula can improve the social disorder of autistic mice, enhance the cognitive ability of BTBR mice, and reverse the lack of social interest and social memory defects of BTBR mice. In addition, for children with unclear diagnosis of mental illness or inability to receive targeted treatment, the formula also shows a certain therapeutic effect and has broad application prospects.
[0051] 2) The Chinese medicine prescription of the present invention adds a purgative drug on the basis of tonifying, treating both the symptoms and the root cause, and has a better therapeutic effect:
[0052] The core is to stabilize the foundation of the child, so this prescription can not only treat ASD or mental illness symptoms, but also strengthen the body. This shows that the prescription for opening up the mind and improving intelligence provided by the present invention may be a broad-spectrum ASD prevention and treatment drug, and its application in the treatment of ASD may help seize the golden period of ASD treatment for children, so as to improve the prognosis and even prevent the occurrence of ASD. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1This is the interaction network between the target genes of the new compound and autism genes. Green represents autism genes, pink represents drug target genes, the degree value of the circle on the right decreases from the inside to the outside, and the genes connected by the red line show the interaction relationship of key genes.
[0054] Figure 2 This is the interaction network between the new compound GRIN2A target gene and autism gene. In the figure, green represents autism genes and pink represents drug target genes. It shows the specific interaction relationship between GRIN2A target genes and autism genes, and emphasizes the importance of GRIN2A in treatment.
[0055] Figure 3 This is a bubble diagram of the interaction between the target gene of the new compound drug and the autism gene. The red line in the figure marks the pathway of the project research content, among which Figure A is Dopaminergic synapse; Figure B is Circadian entrainment; Figure C is mTORsignaling pathway; Figure D is Amphetamine addition; Figure E is Pythway in cancer; Figure F is AGE-RAGE signaling pathway in diabetic complications; Figure G is Phospholipase Dsignaling pathway; the bubble diagram shows the specific interaction of these pathways, which is convenient for understanding the impact of drugs on different pathways.
[0056] Figure 4 It is the Dopaminergic synapse pathway. The red box in the figure shows the key gene of ASD, the blue box shows the drug target gene, and the red dotted and solid lines indicate the possible pathways, showing the mechanism of affecting ASD through the dopamine synapse pathway. The drug's DRD1, DRD2, DRD5, SLC6A3, and AKT1 genes respectively affect the GRIN2A gene of ASD through the Dopaminergic synapse pathway, thereby improving the symptoms of ASD. The GRIN2A gene of ASD is located at the downstream of the drug target gene.
[0057] Figure 5 It is a cell MTT experiment result diagram, which shows the neuronal activity trend of cells treated with different concentrations of compound at 24h and 48h and the neuronal activity trend of cells in the normal group; in the figure, the normal group (C), the group with aconite root (Fuzi), and the groups with different concentrations of the Chinese medicine prescription of the present invention (0.03125mg / mL, 0.0625mg / mL, 0.125mg / mL, 0.25mg / mL, 0.5mg / mL).
[0058] Figure 6The figure is a flow cytometry experiment diagram. The neuronal activity of cells treated with different concentrations of the compound within 24 hours and the neuronal activity trend of cells in the normal group. The figure shows the normal group (C), the group with aconite (Fuzi), and the groups with different concentrations of the Chinese medicine formula of the present invention (0.03125mg / mL, 0.0625mg / mL, 0.125mg / mL).
[0059] Figure 7 The open field test statistical chart, Figure A is the behavioral statistical results before drug administration, Figure B is the behavioral statistical results after drug administration. From left to right, the total moving distance, average speed, time and distance to enter the central area of different groups are statistical results; *: p < 0.05, **: p < 0.01, ***: p < 0.005, ns: p > 0.05, * indicates compared with the WT group, # indicates compared with the C group, P < 0.05 is considered to be statistically significant.
[0060] Figure 8 Figure 1 is an open field test diagram, where Figure A is a heat map of the open field test after drug administration, and Figure B is a track map of the open field test after drug administration. The red box in the figure distinguishes the edge area (Peir zone) and the center area (Center zone), which intuitively shows the activity trajectory and distribution of mice, further supporting the statistical results.
[0061] Fig. 9 The statistical chart of the experimental time percentage of new objects. The percentage of time spent exploring new objects and old objects in different groups. Figure A shows the behavioral test results before drug administration, and Figure B shows the behavioral test results after drug administration. *: p<0.05, **: p<0.01, ***: p<0.005, ns: p>0.05, * indicates comparison with WT, # indicates comparison with group C, P<0.05 is considered to be statistically significant. The percentage of time spent exploring new objects and old objects in different groups.
[0062] Fig.10 Figure A is a heat map of the new object experiment after drug administration, and Figure B is a trajectory map of the new object experiment after drug administration. In the figure, the square is the old object (Old object) and the circle is the new object (New object).
[0063] Fig.11 This is the OPLS-DA model score diagram before drug administration. The green in the figure represents wild-type C57BL / 6 (C57 / WT) mice, and the dark blue represents BTBR T+Itpr3tf / J (BTBR / C) autism model mice.
[0064] Fig.12Figure 1 is a trend chart of the proportion of time in the three-box social experiment of mice. Figure A is the behavioral test results and social preference index statistics of the first stage (Socialblity) after drug administration. Figure B is the behavioral test results and social preference index statistics of the second stage (Social Novelty) after drug administration. In the figure, S1 represents stranger mouse 1, E1 represents empty cage, S2 represents stranger mouse 2, *: p<0.05, **: p<0.01, ns: p>0.05, * indicates comparison with WT, # indicates comparison with group C, P<0.05 is considered to be statistically significant.
[0065] Fig.13 Figure 2 is a diagram of the three-box social experiment for mice. Figure A is the trajectory diagram of the three-box social experiment for mice after drug administration. Figure B is the heat map of the three-box social experiment for mice after drug administration. In the figure, S1 represents stranger mouse 1, E1 represents an empty cage, and S2 represents stranger mouse 2. DETAILED DESCRIPTION
[0066] The technical scheme of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, but the present invention is not limited to the following technical scheme. It should be noted that if the specific technology or conditions are not specified in the embodiments, the experimental results can be obtained according to the description of the relevant literature in the field or the product description. The reagents, instruments, cells and animal models used are all conventional products that can be purchased on the market if the manufacturer is not specified.
[0067] Example 1 A prescription for invigorating the mind and improving intelligence is prepared from the following drugs in parts by weight: 60 g of aconite root, 30 g of ginseng, 30 g of dried ginger, 15 g of evodia rutaecarpa, 30 g of tuckahoe, 30 g of choledochus, 25 g of atractylodes macrocephala, and 25 g of gastrodia elata;
[0068] Example 2: A prescription for invigorating the mind and improving intelligence, prepared from the following drugs in parts by weight: 6 g of aconite root, 6 g of ginseng, 6 g of dried ginger, 3 g of cornus officinalis, 10 g of tuckahoe, 6 g of cholerae arisaema, 3 g of atractylodes macrocephala, and 6 g of gastrodia elata;
[0069] The difference between Example 3 and Example 1 is that it also includes 30g of Acorus calamus, 20g of Ligusticum chuanxiong, 30g of Angelica dahurica, and 10g of Licorice.
[0070] The difference between Example 4 and Example 2 is that it also includes 3g of Acorus calamus, 6g of Ligusticum chuanxiong, 3g of Angelica dahurica and 5g of Licorice.
[0071] Example 5: A prescription for invigorating the mind and improving intelligence, prepared from the following drugs in parts by weight: 10 g of aconite root, 12.5 g of ginseng, 10 g of dried ginger, 5 g of evodia rutaecarpa, 10 g of tuckahoe, 10 g of arisaema cinerea, 5 g of atractylodes macrocephala, and 10 g of gastrodia elata;
[0072] Example 6 is a prescription for invigorating the mind and improving intelligence, which is composed of 27.026g of granules of ground aconite 10g, ginseng 12.5g, dried ginger 10g, Evodia rutaecarpa 5g, Poria 10g, Arisaema cinerea 10g, Atractylodes macrocephala 5g, Gastrodia elata 10g, Acorus gramineus 7.5g, Ligusticum chuanxiong 5g, Angelica dahurica 5g, and Licorice 5g.
[0073] Example 7 Preparation method
[0074] 1. Soak the granular drug described in Example 6 in 8-10 times the amount of physiological saline or complete culture medium at 37°C for 10 minutes, then crush it using an ultrasonic crusher for 3 minutes, filter and collect it with qualitative filter paper, and then use it for animal experiments and cell experiments respectively;
[0075] 2. Then, filter the mixture again using a 0.22 μm sterile filter until the decoction is sterile and transparent. Collect all the decoctions, mix them evenly, and concentrate them into a suspension. Store them in a refrigerator at 4°C.
[0076] Example 8 Joint Analysis of ASD-Drug Gene Interaction Network
[0077] The BATMAN, STRING, DAVID and other databases and Cytoscape software were used for analysis to detect the interaction between the key genes of autism and the target genes of the Chinese medicine formula of the present invention, so as to evaluate the possible pharmacodynamic pathways and potential therapeutic effects of the Chinese medicine formula of the present invention.
[0078] The inventors conducted network pharmacology and bioinformatics analysis and obtained 775 target genes of the compound. Protein interaction analysis showed that the target genes of these drugs have a close interaction relationship with ASD genes ( Figure 1 The inventors further analyzed and discovered 13 ASD-drug gene interaction networks with ASD genes as core genes, represented by GRIN2A ( Figure 2 ). The inventors performed functional enrichment analysis on the genes in these 13 interaction networks using the DAVID database and found that these genes were enriched in pathways that may be related to ASD ( Figure 3 ), and the target gene of the compound is located upstream of the ASD gene in the above 7 pathways, and has a regulatory effect on the ASD gene. Among them, the dopaminergic synaptic pathway has been confirmed to be related to a variety of childhood mental illnesses.
[17] , the five drug target genes (DRD1, DRD2, DRD5, SLC6A3, AKT1) enriched in this pathway are located upstream of the ASD gene (GRIN2A) ( Figure 4 ); and some studies have shown that DRD1 may be involved in neuronal growth and development
[25] DRD2 and DRD5 are involved in the regulation of movement, reward, reinforcement, memory and learning
[26] , SLC6A3 is associated with a variety of neuropsychiatric diseases
[27] and AKT1 regulates metabolism, proliferation, cell survival, growth, and angiogenesis
[28] This suggests that the Chinese medicine formula of the present invention may be used as a drug for the prevention and treatment of autism.
[0079] Example 9 Human hippocampal neural cell culture experiment
[0080] 1. Drug treatment: The prescription for improving intelligence obtained in Example 7 was placed in a 50 mL centrifuge tube, and complete culture medium (10% fetal bovine serum, 1% penicillin-streptomycin, 89% high-glucose culture medium DMEM added to 50 mL) was added according to the concentration, and filtered after a 37°C water bath to prepare a solution with a concentration of 100 mg / mL. When the cells grow to 70%, the drugs were added to the culture plate in a concentration gradient. After 24 hours of culture, MTT and flow cytometry were performed to determine the effects of the drugs on neurons and to determine the most suitable drug concentration. The cell experiment used a decoction prepared with a complete culture medium, and the decoction was the decoction obtained by the method of Example 3.
[0081] 2. MTT experiment: MTT test was used to detect the proliferation ability of cells (HPPNCs) under different concentration gradient treatment. When the cells grew to about 90%, they were digested and passaged. After centrifugation, the cells were resuspended and counted, and 3000 cells / well were plated. A 96-well plate was used, and PBS was added to the outer circle. 100ul of cell fluid was added to each well of the remaining wells. After 6-12h of culture, the cells were attached to the wall, the culture medium was aspirated, and the corresponding concentration of drugs was added. Three replicate wells were set, and the culture medium was changed every two days. 20ul MTT reagent was added after 24h and 48h of incubation with drug f, and incubated for 2h at 37℃ and 5% CO2. The absorbance value at 450nm was read on the microplate reader. The more and faster the cell proliferation, the higher the absorbance; the greater the cytotoxicity, the lower the absorbance. The effect of tonic drugs on neuronal vitality was investigated.
[0082] 3. Flow cytometry apoptosis detection: After 24 hours of incubation with drugs, collect the cell culture supernatant first. Then digest with EDTA-free trypsin (G4002 or G4011 is recommended), combine with the cell culture supernatant, and collect the cells by centrifugation at 500g and 4℃ for 5 minutes. Trypsin digestion time should not be too long to avoid false positives caused by excessive digestion; wash the cells twice with pre-cooled PBS (G4202 is recommended), centrifuge at 500g and 4℃ for 5 minutes each time to collect the cells; gently resuspend the cells with pre-cooled 1×Binding Buffer and adjust the cell concentration to 1-5×106 / mL; take 100μL of cell suspension, add 5μL Annexin V-FITC and 5μL PI, mix gently, and keep at room temperature away from light for 8-10 minutes; add 400μL pre-cooled 1×Binding Buffer, shake gently, and detect with flow cytometer or fluorescence microscope within 1 hour.
[0083] 4. Data statistics and drawing: All data were statistically analyzed using SPSS 26.0, and the significance of differences was compared by variance analysis. The test results were considered statistically significant when P < 0.05. Statistical graphs were drawn in GraphPad prism 8 software.
[0084] The results show:
[0085] (1) MTT experiment: Compared with the normal group and the positive group, when the concentration of the Chinese medicine decoction of the present invention is 0.0625 mg / mL, it will not affect the cell activity ( Figure 5 ). Specifically, the metabolic activities of the cells at this concentration were similar to those of the normal group, indicating that the Chinese medicine decoction of the present invention had no toxic effect on the cells at this concentration.
[0086] (2) Cell apoptosis experiment: The inventors analyzed the cell apoptosis after 24 h and found that, compared with the normal group, the concentration of 0.0625 mg / mL did not accelerate the apoptosis of HPPNCs; more significantly, compared with the positive group (FUZi), the Chinese medicine decoction of the present invention not only did not increase the apoptosis rate of cells, but reversed the apoptosis process to a certain extent and improved the activity of HPPNCs ( Figure 6 ). This means that the Chinese medicine formula of the present invention can protect cells from apoptosis to a certain extent and maintain the normal function of cells. The above results all suggest that the Chinese medicine formula of the present invention has the potential to be used as a drug for preventing and antagonizing ASD.
[0087] Example 10 Behavioral changes in model mice before and after administration
[0088] 1. Animal administration: The animal experiment uses physiological saline to prepare the decoction, which is the decoction obtained by the method of Example 3, and is diluted to different concentrations according to the experimental requirements. The most suitable drug concentration is calculated with reference to "Methodology of Pharmacological Research of Traditional Chinese Medicine", and the drug concentration for mice is set. 21-day BTBR (black and tan, brachyuric) mice are gavaged, and the normal WT group (WT-0.9% NaCl group), C group (BTBR-0.9% NaCl group), BTBR-0.5xFF group (0.32 mg / g), BTBR-1xFF group (0.64 mg / g) and BTBR-2xFF group (1.28 mg / g) are tested for relevant indicators before and after 2 weeks of administration.
[0089] 2. Behavioral testing:
[0090] (1) Open field experiment: Place the mouse in the center of the open field and start the recording system, either by video or manual recording. Use professional software to analyze the recorded data, calculate the mouse's residence time in different areas, movement speed, and avoidance of edge areas, and thus assess the anxiety state of the mouse. Normal mice show a high level of activity and desire to explore, usually moving freely in the center and edge areas of the field, showing a moderate level of anxiety; abnormal mice (such as autism model mice) may show significantly reduced activity levels and exploratory behavior, mainly wandering around the edge of the field, avoiding entering the central area, showing a high level of anxiety and difficulty adapting to the new environment.
[0091] (2) New object experiment: Phase 1, adaptation period, two identical objects (AB, make sure the objects have no odor and cannot be pushed) are placed in the device, 10 cm away from the two side walls, and the mouse is placed in the device with its back facing the objects from the same distance from the objects. The mouse is placed in the experimental device (without objects) and moves freely for 10 minutes. Phase 2, test period, generally 1 hour after the completion of Phase 2 is selected as the time interval for testing memory (longer time intervals can be used to evaluate the effect of improving memory). Replace one of the two identical objects with a different object (AC or BC) and place it in the device. Similarly, the mouse is placed in the device with its back facing the objects from the same distance from the objects for 10 minutes. Use a camera and software to record the time the mouse explores each object (the exploration of the object is counted as the mouth or nose touching the object and getting close to the object within about 2-3 cm). The number, time and distance of the animal's exploration of each object are measured. Normal mice show a strong interest in new objects, tend to spend more time exploring new objects, and display good cognitive function and memory ability; while abnormal mice (such as neurodevelopmental disorder model mice) have no significant difference in the exploration time of new and familiar objects, and their overall exploratory behavior is reduced, showing defects in cognitive function and memory ability.
[0092] (3) Three-box social experiment: evaluate the social ability, social novelty and social memory of mice. Phase 1: On both sides of the three boxes, a strange mouse of the same species, Stranger1 (S1), was placed on one side, and there was only an empty metal cage (E1) on the other side, allowing the test mice to move freely in the three boxes. Phase 2: Another strange mouse of the same species, Stranger2 (S2), was placed on the other side, and the test mice were also allowed to move freely in the three boxes. Data such as the time the mice entered each small chamber, the number of times they entered the small chamber, and the sniffing time of each cage were collected. In the first phase of the experiment, normal mice communicated with S1 more often and for more time than with the empty cage E1. In the second phase, they were more willing to interact with the new mouse S2 when faced with the new mouse S2 and the old mouse S1, showing good social memory and interaction ability. However, abnormal mice (such as autism model mice) showed similar interest in the room with the strange mouse S1 and the room with the empty cage E1, or preferred the empty cage E1, and had no significant preference between the new mouse S2 and the old mouse S1, indicating that they lacked social interest and had social memory defects.
[0093] 3. Sample collection: After the behavioral test, the mice were euthanized and blood was quickly collected from the heart, which was then divided into anticoagulant tubes for Chinese medicine group, metabolic group, blood routine and blood biochemistry tests. The liver, kidney, heart and brain were removed, and the midline of the brain was evenly divided into two halves, one half of which was fixed and cut into thin slices for neurodegeneration testing, and the other half of the brain was placed in a cryopreservation tube, and each cryopreservation tube was numbered according to the numbering rules (mouse information, batch, date), and placed in a liquid nitrogen tank for freezing and testing.
[0094] The results show:
[0095] (1) Open field test: Before drug administration, BTBR mice had no significant difference from WT mice in total moving distance, average speed and center distance, but their center activity time was significantly reduced, indicating that their anxiety level was higher ( Figure 7 A). Specifically, before drug administration, BTBR mice spent significantly less time in the center area than WT mice, and generally stayed more at the edge of the field, a typical manifestation of anxiety behavior. After 2 weeks of drug administration, the total movement distance, average speed, and center distance of BTBR mice increased significantly, while the center activity time also recovered ( Figure 7 B). Compared with WT mice before administration, BTBR mice after 2 weeks of administration showed significant improvements in these indicators, indicating that Kaiqiao Yizhi prescription may increase the activity level of BTBR mice and improve their anxiety behavior in the open field. Heat maps and trajectory maps further support this finding ( Figure 8). The heat map showed that the activity density of BTBR mice in the central area of the open field increased significantly after drug administration, while the track map showed that their movement paths were more uniform throughout the experimental field. These results indicate that Kaiqiao Yizhi Recipe has a significant effect in improving the anxiety behavior of BTBR mice.
[0096] (2) Novel object test: Before drug administration, BTBR mice showed no significant difference in the exploration time between new and old objects, and compared with the WT group, they did not show a significant preference for novel objects ( Fig. 9 A). This indicates that BTBR mice cannot effectively distinguish between new objects and familiar objects, showing a deficiency in cognitive function. After 2 weeks of administration, the exploration time of BTBR mice on new objects increased significantly in the different concentration administration groups, indicating that Kaiqiao Yizhi Fang can enhance the cognitive ability of BTBR mice ( Fig. 9 B). Specifically, BTBR mice treated with the Kaiqiao Yizhi formula spent more time exploring novel objects than familiar objects. The results of the heat map and trajectory map further support this finding ( Fig.10 ), these figures show that mice showed more interest and activity in the experimental field, and the exploration paths were more complex and diverse. Through the analysis of the experimental data of novel objects, we can conclude that Kaiqiao Yizhi Recipe can effectively improve the cognitive function and memory ability of BTBR mice.
[0097] (3) Three-box social experiment: After 2 weeks of administration of the Kaiqiao Yizhi formula, the behavioral performance of BTBR mice in both stages was significantly improved. In the first stage, compared with the BTBR group mice fed with normal saline, the mice in the BTBR-1xFF group showed a stronger tendency to contact the unfamiliar mouse S1, and the activity time and frequency near S1 were significantly longer, showing a higher social preference; in the second stage, the mice in the BTBR-1xFF group were more inclined to interact with the new mouse S2 rather than the familiar mouse S1, indicating that their social memory and preference were restored. This behavioral pattern is closer to the performance of the WT group mice, showing that the Kaiqiao Yizhi formula significantly improved the social function of BTBR mice ( Fig.12 ). These mice also spent more time interacting with the novel stimulus, a finding supported by heat maps and trajectory plots ( Fig.13 ), indicating that Kaiqiao Yizhi formula reversed the lack of social interest and social memory deficits in BTBR mice.
[0098] In summary, the Kaiqiao Yizhi prescription can not only significantly improve the neuronal activity of HPPNCs cells, but also improve the social level of autism animal model mice, which proves that the prescription is expected to be used for the treatment of autism.
[0099] Example 11 Clinical application of the prescription for invigorating the kidney and improving intelligence
[0100] The inventor team used the Kaiqiao Yizhi formula to treat 12 cases of "five delays and five softness" from 2015 to 2018.
[0101] The children received treatment, and after treatment, their parents reported that their children's communication, social interaction, language and behavioral abilities had improved significantly. A retrospective review of the cases revealed that 3 of them were diagnosed with autism by Western medicine, and 9 were diagnosed with mental retardation.
[0102] Table 1 Comparison table of case records of clinical application of Kaiqiao Yizhi prescription
[0103]
[0104] All the above patients received the treatment of Kaiqiao Yizhi Recipe for at least 4 months, during which no obvious side effects were observed, and the patients' physical condition was significantly improved. This suggests that the Kaiqiao Yizhi Recipe provided by the present invention may be a broad-spectrum ASD prevention and treatment drug, and its application in the treatment of ASD may help seize the golden period of ASD treatment in children, so as to improve the prognosis and even prevent the occurrence of ASD.
[0105] In summary, the present invention fully demonstrates the effectiveness and advantages of the Kaiqiao Yizhi recipe in treating childhood autism or childhood mental illness, especially early ASD.
Claims
1. A Chinese medicine composition for invigorating the mind and improving intelligence, characterized in that: The invention is prepared from the following medicines in parts by weight: 6-60g of aconite root, 6-30g of ginseng, 6-30g of dried ginger, 3-15g of evodia rutaecarpa, 10-30g of tuckahoe, 6-30g of arisaema, 3-30g of atractylodes macrocephala, and 6-30g of gastrodia elata.
2. The Chinese medicine composition for improving resuscitation and improving intelligence according to claim 1, characterized in that: The traditional Chinese medicine composition also includes 3-30g of Acorus calamus, 3-20g of Ligusticum chuanxiong, 3-30g of Angelica dahurica and 3-10g of Licorice.
3. The Chinese medicine composition for improving resuscitation and improving intelligence according to claim 2, characterized in that: It is made of the following medicines in parts by weight: 10g of aconite root, 12.5g of ginseng, 10g of dried ginger, 5g of evodia rutaecarpa, 10g of tuckahoe, 10g of arisaema cinerea, 5g of atractylodes macrocephala, 10g of gastrodia elata, 7.5g of calamus, 5g of chuanxiong, 5g of angelica dahurica, and 5g of liquorice.
4. Use of the Chinese medicine composition for improving resuscitation and improving intelligence according to any one of claims 1 to 3 in the preparation of drugs for autism and children's mental illness.
5. The use according to claim 4, characterized in that: The dosage form of the Chinese medicine composition is decoction, granules, or honey pills or syrup.
6. The use according to claim 5, characterized in that: The method for preparing the Chinese medicine composition decoction comprises the following steps: 1) The granules composed of the crushed Chinese medicine composition according to claim 1 are soaked in 8-10 times the amount of physiological saline or complete culture medium at 37°C for 10-15 minutes, then crushed with an ultrasonic crusher for 3-5 minutes, filtered and collected with qualitative filter paper for later use; 2) Further filter, use a 0.22 μm sterile filter to filter until the decoction is transparent, collect all the decoctions, mix them evenly, and then concentrate them into a suspension, which is stored in a refrigerator at 4° C. for later use.
7. The use according to claim 5, characterized in that: The concentration of the Chinese medicine composition decoction is not less than 0.0325 mg / mL.
8. The use according to claim 7, characterized in that: The concentration of the Chinese medicine composition decoction is not less than 0.0625 mg / mL.
Citation Information
Patent Citations
Medicine for treating yang deficiency type depression and preparation method thereof
CN114796428A
Radix aconiti carmichaeli decoction preparation for treating yang deficiency and cold syncope
CN115957288A
Calming and desadening pill preparing process thereof
CN1171264A
